Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling
Science Translational Medicine · 15.07.2026 · 18 (858)
DOI: 10.1126/scitranslmed.aef2269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 15.07.2026. Verfasst von Robert Clarke und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Cal…. Hauptthemen laut MEDLINE: Amphiregulin, Oligodendroglia, Signal Transduction, ErbB Receptors. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Centres de Recerca de Catalunya, Breakthrough T1D Canada.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that results from oligodendrocyte loss and multifocal demyelination of the CNS white matter. Current therapies can suppress the progression of CNS inflammation but do not actively promote tissue repair. Nanoparticles (NPs) coated with CNS-specific peptide–major histocompatibility complex class II (pMHCII) molecules can alleviate disability in mice with experimental autoimmune encephalomyelitis (EAE) by triggering the formation, expansion, and recruitment of antigen-specific type 1 regulatory CD4 + T cells (Tr1 cells). By investigating the effects of pMHCII-NP therapy on focal demyelinated lesions in the spinal cord induced by lysolecithin and sustained by chronic autoimmune encephalitogenic insults, here, we show that CNS antigen–specific Tr1 cells promote oligodendrogenesis, the preservation of axon caliber, and remyelination. Cell-specific deletion of amphiregulin ( Areg ) in T cells or of the epidermal growth factor receptor ( Egfr ) in oligodendrocytes abrogated these therapeutic outcomes. Oligodendrocyte-specific deletion of Egfr did not impair the pharmacodynamic or anti-inflammatory effects of pMHCII-NP treatment. These findings indicate that the oligodendrocyte-mediated therapeutic effects of pMHCII-NP treatment are dissociated from the anti-inflammatory properties of Tr1 cells; instead, they involve Tr1 cell–derived Areg to activate oligodendrocytes in an EGFR-dependent manner. Together, these results indicate that antigen-specific regulatory T cells can promote oligodendrogenesis and highlight the amphiregulin-oligodendrocyte EGFR pathway as a target for therapeutic intervention in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology, and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
- Hotchkiss Brain Institute and Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
- Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, 08036, Spain.
- School of Medical Sciences, Faculty of Health, University of Victoria, Victoria, British Columbia V8W 2Y2, Canada.
- Institute of Aging and Lifelong Health, University of Victoria, Victoria, British Columbia V8W 2Y2, Canada.
- Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
ORCID-Profile: Robert Clarke, Atefeh Rayatpour, Josep Garnica, Saswat Mohapatra, Joel Moro, Debajyoti Mondal, Marlene T Morch, Colin J Murray, Cameo Volk, Marie-Eve Tremblay, V Wee Yong, Pere Santamaria
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Centres de Recerca de Catalunya
- Breakthrough T1D Canada
- Canadian Institutes of Health Research
- Instituto de Salud Carlos III
- Praespero
- Canada Foundation for Innovation
Zitieren
APA
Clarke, R., Rayatpour, A., Garnica, J., Lozinski, B. M., Lee, J., Mohapatra, S., Yamanouchi, J., Moro, J., Mondal, D., Morch, M. T., Khakpour, M., Murray, C. J., Volk, C., Tremblay, M. E., Serra, P., Yang, Y., Yong, V. W., & Santamaria, P. (2026). Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling. Science Translational Medicine, 18(858). https://doi.org/10.1126/scitranslmed.aef2269
Vancouver
Clarke R, Rayatpour A, Garnica J, Lozinski BM, Lee J, Mohapatra S, et al. Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling. Science Translational Medicine. 2026;18(858). doi:10.1126/scitranslmed.aef2269
BibTeX
@article{Clarke2026,
author = {Clarke, Robert and Rayatpour, Atefeh and Garnica, Josep and Lozinski, Brian M and Lee, Justin and Mohapatra, Saswat and Yamanouchi, Jun and Moro, Joel and Mondal, Debajyoti and Morch, Marlene T and Khakpour, Mohammadparsa and Murray, Colin J and Volk, Cameo and Tremblay, Marie-Eve and Serra, Pau and Yang, Yang and Yong, V Wee and Santamaria, Pere},
title = {Murine autoantigen-specific type 1 regulatory T cells promote oligodendrogenesis through amphiregulin-EGFR signaling},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {858},
doi = {10.1126/scitranslmed.aef2269}
}
EUVIMED